PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Phase I Waiver Plan 'Very Positive'
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.
The new measure aims to attract more bioventure-oriented products into the Japanese market. The country has been easing requirements for local Phase I trials gradually over the past decade.